Molecular signatures of ovarian cancer: From detection to prognosis

Molecular Diagnosis and Therapy

Volumn 14, Issue 1, 2010, Pages 13-22

  Walsh, Christine S ^a   Karlan, Beth Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; AUTOTOXIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CLAUDIN 3; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; KALLEKREIN; LEPTIN; LIPID ASSOCIATED SIALIC ACID; LIPOPHOSPHATIDIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MESOTHELIN; MYOGLOBIN; OSTEOPONTIN; PLACENTA PROTEIN 14; PROLACTIN; PROTEIN HE 4; PROTEIN OVX 1; SOMATOMEDIN B; TENASCIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DNA MICROARRAY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; GENE EXPRESSION; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 76949089172     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256349     Document Type: Review

References (65)

1. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary: FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 Suppl. 1: S161-92
2. Hogg R, FriedlanderM. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22 (7): 1315-1327
3. Wilson JMG, Junger G. Principles and practice of screening for disease: public health papers. Geneva: WHO, 1968
4. van Nagell Jr JR, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77 (3): 350-356
5. Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192 (4): 1214-21; discussion 1221-1222
6. Liede A, Karlan BY, Baldwin RL, et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002; 20 (6): 1570-1577
7. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 2009; 6 (7): e1000114 [online]. Available from URL: http://www.plosmedicine.org/article/info% 3Adoi%2F10.1371%2Fjournal.pmed.1000114 [Accessed 2009 Nov 30]
8. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76 (10 Suppl.): 2004-2010
9. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol 2005; 23 (2): 293-300
10. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3 (4): 355-366
11. Bast Jr RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68 (5): 1331-1337
12. Bast Jr RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309 (15): 883-887
13. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8 (9): 813-821
14. Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993; 85 (21): 1748-1751
15. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005; 58 (3): 308-312
16. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193 (5): 1630-1639 (Pubitemid 41540458)
17. PartridgeE,KreimerAR,GreenleeRT, et al.Results fromfour rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113 (4): 775-782
18. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10 (4): 327-340
19. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21 (6 Suppl.): 273-309S
20. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21 (10 Suppl.): 206-210
21. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithmto screen for ovarian cancer. J ClinOncol 2005; 23 (31): 7919-7926
22. Sato S,Yokoyama Y, Sakamoto T, et al.Usefulness ofmass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000; 89 (3): 582-588
23. DePriest PD, Gallion HH, Pavlik EJ, et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997; 65 (3): 408-414
24. Bast Jr RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21 (10 Suppl.): 200-205
25. Rapkiewicz AV, Espina V, Petricoin III EF, et al. Biomarkers of ovarian tumours. Eur J Cancer 2004; 40 (17): 2604-2612
26. Skates SJ, Horick N, Yu Y, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22 (20): 4059-4066
27. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95 (1): 9-15
28. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobeadbased cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (4): 981-987
29. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18 (5): 1365-1372
30. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 (9306): 572-577
31. Zhang Z, Bast Jr RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64 (16): 5882-5890
32. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102 (21): 7677-7682
33. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14 (4): 1065-1072
34. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; 110 (3): 374-382
35. Amonkar SD, Bertenshaw GP, Chen T-H, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009; 4 (2): e4599 [online]. Available from URL: http://www.plosone.org/article/ info%3Adoi%2F10.1371%2Fjournal.pone.0004599 [Accessed 2009 Nov 30]
36. Bouchard D, Morisset D, Bourbonnais Y, et al. Proteins with wheyacidic- protein motifs and cancer. Lancet Oncol 2006; 7 (2): 167-174
37. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000; 60 (18): 5007-5011
38. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001; 98 (3): 1176-1181
39. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108 (2): 402-408
40. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63 (13): 3695-3700
41. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112 (1): 40-46
42. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23 (36): 9338-9343
43. Allard J, Somers E, Theil R, et al. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer [abstract no. 5535]. J Clin Oncol 2008; 26 (15S): 5535 [online]. Available from URL: http://meeting. ascopubs.org/ cgi/content/abstract/26/15-suppl/5535 [Accessed 2009 Nov 30]
44. Rustin GJ, van der Burg ME, on behalf ofMRCandEORTC Collaborators.A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract no. 1]. J Clin Oncol 2009; 27 (18S): 1 [online]. Available from URL: http://meeting.ascopubs.org/ cgi/content/abstract/27/18S/1 [Accessed 2009 Nov 30]
45. Meri S, Baumann M. Proteomics: posttranslational modifications, immune responses and current analytical tools. Biomol Eng 2001; 18 (5): 213-220
46. Sellers TA, Yates JR. Review of proteomics with applications to genetic epidemiology. Genet Epidemiol 2003; 24 (2): 83-98
47. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003; 4: 24 [online]. Available from URL: http://www.biomedcentral.com/1471-2105/4/24 [Accessed 2009 Nov 30]
48. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004; 20 (5): 777-785
49. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. JNatl Cancer Inst 2004; 96 (5): 353-356
50. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer [letter]. Lancet 2002; 360 (9327): 169; author reply 170-171
51. Pearl DC. Proteomic patterns in serum and identification of ovarian cancer [letter]. Lancet 2002; 360 (9327): 169-70; author reply 170-171
52. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer [letter]. Lancet 2002; 360 (9327): 170; author reply 170-171
53. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11 (2): 163-178
54. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2872-2881
55. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003; 100 (21): 12343-12348
56. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5 (17): 4589-4596
57. McIntosh M, Anderson G, Drescher C, et al. Ovarian cancer early detection claims are biased [letter]. Clin Cancer Res 2008; 14 (22): 7574; author reply 7577-7579
58. Coates RJ, Kolor K, Stewart SL, et al. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use [letter]. Clin Cancer Res 2008; 14 (22): 7575-6; author reply 7577-7579
59. GreeneMH, Feng Z, GailMH. The importance of test positive predictive value in ovarian cancer screening [letter]. Clin Cancer Res 2008; 14 (22): 7574; author reply 7577-7579
60. Wagner L. A test before its time? FDA stalls distribution process of proteomic test. J Natl Cancer Inst 2004; 96 (7): 500-501
61. RifaiN,Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24 (8): 971-983
62. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3 (4): 243-252
63. Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200 (6): 639.e1-5
64. Diamandis EP. Point: proteomic patterns in biological fluids. Do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272-1275
65. Lutz AM, Willmann JK, Cochran FV, et al. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 2008; 5 (8): e170 [online]. Available from URL: http://www.plosmedicine.org/ article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050170 [Accessed 2009 Nov 30]